News
Health Canada approves Reblozyl to treat transfusion-dependent anemia resulting from low/intermediate risk myelodysplastic syndromes. - BMS.
-Bristol Myers Squibb Canada and Acceleron Pharma Inc. announced that Health Canada has approved Reblozyl (luspatercept for injection) for the treatment of adult patients with transfusion-dependent anemia requiring at least two RBC red blood cell (RBC) units over 8 weeks resulting from very low-to intermediate-risk myelodysplastic syndromes (MDS) who have ring sideroblasts and who have failed or are not suitable for erythropoietin-based therapy.
Reblozyl represents a new class of treatment for eligible patients as the first and only approved erythroid maturation agent in Canada.
Condition: Myelodysplastic Syndromes
Type: drug